Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB1 | P18505 | 4/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841444 | 1.00 | GABRB1 (0.37) | GABRB1GABRB2OPRK1LMNAHTT | |
| SCHEMBL17841447 | 1.00 | GABRB1 (0.37) | GABRB1GABRB2OPRK1LMNAHTT | |
| SCHEMBL23112570 | 0.89 | CTSL (0.37) | HTTCTSLCTSSCTSK | |
| SCHEMBL23112568 | 0.89 | CTSL (0.37) | HTTCTSLCTSSCTSK | |
| SCHEMBL23112571 | 0.89 | CTSL (0.37) | HTTCTSLCTSSCTSK | |
| SCHEMBL21981040 | 0.87 | HDAC4 (0.40) | LMNAHTTCTSLCTSSCTSK | |
| SCHEMBL21981041 | 0.87 | HDAC4 (0.40) | LMNAHTTCTSLCTSSCTSK | |
| SCHEMBL31329156 | 0.87 | HDAC4 (0.40) | LMNAHTTCTSLCTSSCTSK | |
| SCHEMBL21981039 | 0.87 | HDAC4 (0.40) | LMNAHTTCTSLCTSSCTSK | |
| SCHEMBL17857574 | 0.83 | MMP8 (0.42) | OPRK1LMNAHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | TNNI3, NME4, TNNT2 | GABRB1 3627/4885GABRB2 3762/4885OPRK1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.